Akari Therapeutics, Plc (CLA.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:16AM CEST. Market open.
Currency in EUR
Valuation measures4
| Market cap (intra-day) | 11.08M |
| Enterprise value | 11.08M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | N/A |
| Price/book (mrq) | 2.96 |
| Enterprise value/revenue | N/A |
| Enterprise value/EBITDA | -0.47 |
Trading information
Stock price history
| Beta (5Y monthly) | N/A |
| 52-week change 3 | -64.64% |
| S&P500 52-week change 3 | 28.04% |
| 52-week high 3 | 4.6400 |
| 52-week low 3 | 0.9450 |
| 50-day moving average 3 | 1.3761 |
| 200-day moving average 3 | 2.4744 |
Share statistics
| Avg vol (3-month) 3 | 13 |
| Avg vol (10-day) 3 | N/A |
| Shares outstanding 5 | 7.92M |
| Implied shares outstanding 6 | N/A |
| Float 8 | 9.56B |
| % held by insiders 1 | 2,017.91% |
| % held by institutions 1 | 2.28% |
| Shares short 4 | N/A |
| Short ratio 4 | N/A |
| Short % of float 4 | N/A |
| Short % of shares outstanding 4 | N/A |
| Shares short (prior month ) 4 | N/A |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:20 |
| Last split date 3 | 17 Aug 2023 |
Financial highlights
Currency in USD.Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | 0.00% |
Management effectiveness
| Return on assets (ttm) | -210.95% |
| Return on equity (ttm) | N/A |
Income statement
| Revenue (ttm) | N/A |
| Revenue per share (ttm) | N/A |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | -18.18M |
| Net income avi to common (ttm) | -16.57M |
| Diluted EPS (ttm) | -1.8800 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 1.31M |
| Total cash per share (mrq) | 0 |
| Total debt (mrq) | N/A |
| Total debt/equity (mrq) | N/A |
| Current ratio (mrq) | 0.44 |
| Book value per share (mrq) | -0.44 |
Cash flow statement
| Operating cash flow (ttm) | -15.6M |
| Levered free cash flow (ttm) | -9.76M |
© 2024 Yahoo. All rights reserved.